Biosimilarity: The FDA Perspective - Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA) - Books - Taylor & Francis Inc - 9781498750394 - July 25, 2018
In case cover and title do not match, the title is correct

Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)
Biosimilarity: The FDA Perspective 1st edition

Price
HK$ 2,335
excl. VAT

Ordered from remote warehouse

Expected to be ready for shipping Oct 27 - Nov 6
Christmas presents can be returned until 31 January
Get notified about new Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA) releases

Our customers say:

14-day return policy in accordance with European consumer protection law
Top ranking on Trustpilot
Add to your iMusic wish list

Not rated yet

The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.

456 pages, 79 colour illustrations, 43 black & white tables

Media Books     Hardcover Book   (Book with hard spine and cover)
Released July 25, 2018
ISBN13 9781498750394
Publishers Taylor & Francis Inc
Pages 398
Dimensions 261 × 187 × 29 mm   ·   1.10 kg
Language English  

More by Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)

Show all

More from the same publisher

See all of Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)